The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.
The drug maker scored its third breakthrough designation label, this time for orphan drug bimagrumab, a possible treatment for a muscle-wasting disease.
FDA’s afatinib approval enables the drug maker set up shop in a new therapy space.
Business briefs: Lilly, Novartis, Activartis, plus policy news
July 8, 2013
4:55 pm
Eli Lilly and Boehringer Ingelheim submit a glargine biosimilar to the EMA; Novartis pipeline claims an Enbrel-superior treatment; Activartis med gets orphan drug status; generics makers may have to pay more attention to labels; Administration tweaks healthcare reform implementation over the long weekend.
Culture of innovation has a sales value, study says
Notes to the advisory committee indicate that recycled data has perceived weak spots.
Company news: Burson-Marsteller, Corcept and Orexigen
August 7, 2012
3:13 pm
PR firm Burson-Marsteller launched a new healthcare subsidiary, Orexigen’s net loss widened in Q2, and Corcept closed out its first full quarter with orphan treatment Korlym.